Search PubMed⌕ Search

Biomedical subjects

M Baltzan

Publications and source records attributed to M Baltzan.

18 recordsLinked to original sources
PubMed2000

Heightened CD40 ligand gene expression in peripheral CD4+ T cells from patients with kidney allograft rejection.

BACKGROUND: CD40 ligand (CD40L) gene expression is increased in rejecting allograft biopsies. We, therefore, tested the possibility that CD40L gene expression is heightened in peripheral CD4+ T cells during renal allograft rejection. METHODS: CD40L gene expression in peripheral blood CD4+ T cells from two renal transplant groups was measured by quantitative reverse transcription-polymerase chain reaction (RT-PCR). Group 1: 20 patients with excellent renal transplant function; group 2: 25 patients with findings of acute and/or chronic allograft nephropathy (CAN); and group 3 of 12 normal controls. CD4+ cells were isolated by positive selection. The modifying effect of cyclosporine (CsA) and FK506 on CD40L gene expression was further tested in vitro in CD4+ T lymphocytes separated from pokeweed mitogen- (PWM) activated peripheral blood lymphocytes (PBL) preparations. RESULTS: Mean+/-SD expressions of CD40L gene, in aM, in groups 1-3 were as follows: 0.0052+/-0.0094; 0.022+/-0.023 (P=0.0038 vs. group 2); and 0.014+/-0.005. Levels of CD40L gene expression correlated significantly with acute rejection Banff 97 score (R2=0.44, P=0.0004) and severity of intertubular capillary changes (ITCC) (R2=0.33, P=0.011). After in vitro activation, CD40L gene expression increased by approximately 4-fold and the addition of CsA or FK506 diminished CD40L gene expression to a base level. CONCLUSION: Peripheral CD4+ T cell CD40L gene expression increases significantly in acute rejection and CAN and may serve as a non-invasive method to monitor allograft function and determine the biological response to CsA and FK506.

Acute Disease↗
PubMed2000

Low-dose inhaled corticosteroids and the prevention of death from asthma.

BACKGROUND: Although inhaled corticosteroids are effective for the treatment of asthma, it is uncertain whether their use can prevent death from asthma. METHODS: We used the Saskatchewan Health data bases to form a population-based cohort of all subjects from 5 through 44 years of age who were using antiasthma drugs during the period from 1975 through 1991. We followed subjects until the end of 1997, their 55th birthday, death, emigration, or termination of health insurance coverage; whichever came first. We conducted a nested case-control study in which subjects who died of asthma were matched with controls within the cohort according to the length of follow-up at the time of death of the case patient (the index date), the date of study entry, and the severity of asthma. We calculated rate ratios after adjustment for the subject's age and sex; the number of prescriptions of theophylline, nebulized and oral beta-adrenergic agonists, and oral corticosteroids in the year before the index date; the number of canisters of inhaled beta-adrenergic agonists used in the year before the index date; and the number of hospitalizations for asthma in the two years before the index date. RESULTS: The cohort consisted of 30,569 subjects. Of the 562 deaths, 77 were classified as due to asthma. We matched the 66 subjects who died of asthma for whom there were complete data with 2681 controls. Fifty-three percent of the case patients and 46 percent of the control patients had used inhaled corticosteroids in the previous year, most commonly low-dose beclomethasone. The mean number of canisters was 1.18 for the patients who died and 1.57 for the controls. On the basis of a continuous dose-response analysis, we calculated that the rate of death from asthma decreased by 21 percent with each additional canister of inhaled corticosteroids used in the previous year (adjusted rate ratio, 0.79; 95 percent confidence interval, 0.65 to 0.97). The rate of death from asthma during the first three months after discontinuation of inhaled corticosteroids was higher than the rate among patients who continued to use the drugs. CONCLUSIONS: The regular use of low-dose inhaled corticosteroids is associated with a decreased risk of death from asthma.

Administration, Inhalation↗
PubMed2000

The generalization of the odds ratio, risk ratio and risk difference to r x k tables.

Familiar measures of association for 2 x 2 tables are the odds ratio, the risk ratio and the risk difference. Analagous measures of outcome-exposure association are desirable when there are several degrees of severity of both exposure and disease outcome. One such measure (alpha), which we label the general odds ratio (OR(G)), was proposed by Agresti. Convenient methods are given for calculation of both standard error and 95 per cent confidence intervals for OR(G). Other approaches to generalizing the odds ratio entail fitting statistical models which might not fit the data, and cannot handle some zero frequencies. We propose a generalization of the risk ratio (RR(G)) following the statistical approaches of Agresti, Goodman and Kruskal. A method of calculating the standard error and 95 per cent confidence interval for RR(G) is provided. A known statistic, Somers' d, fulfils the characteristics necessary for a generalized risk difference (RD(G)). These measures have straightforward interpretations, are easily computed, are at least as precise as other methods and do not require fitting statistical models to the data. We also examine the pooling of such measures as in, for example, meta-analysis.

Anti-Ulcer Agents↗
PubMed1999

Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis.

Sarcoidosis may cause severe ventilatory impairment requiring corticosteroid treatment. Chloroquine (CQ) can be an effective treatment for lung sarcoidosis with few side effects, but has not been accepted as standard therapy. We investigated the benefits of prolonged CQ therapy in 23 symptomatic patients with biopsy-proven pulmonary sarcoidosis (duration, >/= 2 yr). Patients were initially treated for 6 mo with CQ, 750 mg/d, tapering every 2 mo to 250 mg/d. Eighteen patients were then randomized to either a Maintenance group (CQ, 250 mg/d) or to an Observation group (no CQ). After the initial treatment, significant improvement was observed in symptoms, pulmonary function, angiotensin-converting enzyme, and lung gallium scan. Patients randomized to the Maintenance group showed a slower decline in pulmonary function (FEV1, 51.4 +/- 28.2 ml/yr [Maintenance] versus 196.3 +/- 33.4 ml/yr [Observation], p < 0.02) and had fewer relapses: 2 of 10 patients in the Maintenance group at 29.5 +/- 4.9 mo versus 6 of 8 patients in the Observation group at 15.5 +/- 2.9 mo. Adverse effects were seen mainly during high-CQ dosage. We conclude that CQ should be an important consideration for the treatment and maintenance of chronic pulmonary sarcoidosis.

Adult↗
PubMed1997

Fate of recurrent acute interstitial cellular rejection in an HLA identical kidney transplant recipient: impact of donor microchimerism.

We and others have shown that the incidence of acute interstitial rejection in HLA identical and non-identical kidney transplantation is similar. Chronic vascular rejection is, however, rare in full matched recipients. In light of the known correlation between previous acute cellular and chronic vascular rejections, lack of chronic rejection in full matched kidney allografts suggest that the immunological basis of acute and chronic rejections are different and/or only high-grade acute cellular rejection leads to chronic vascular rejection. Herein, we present the case of an HLA identical kidney transplant from a male donor to a female recipient who, because of poor compliance, had frequent acute interstitial cellular rejection culminating into chronic interstitial fibrosis with no evidence of vasculopathy or glomerulopathy characteristic of chronic vascular rejection. Donor cells, as examined by the presence of the Y chromosome DNA, were present in the peripheral blood during the most recent acute rejection but not thereafter. These findings support the notion that acute interstitial cellular rejection can lead to interstitial fibrosis but not chronic vasculopathy/glomerulopathy, and that microchimerism did not confer protection against acute cellular rejection.

Adult↗
PubMed1995

Lack of early acute rejection does not predict safe tapering of immunosuppression.

In an effort to reduce long-term complications of immunosuppressive medications, some investigators have devised protocols of reduced dosage [Kupin et al. 1988, Kelly et al. 1989, Reinsmoen et al. 1993] which are intended to maintain the stability of the transplant and at the same time prevent or retard immunosuppressive medication side effects. Implicit in this plan is the assumption that there has been the development of some degree of graft acceptance [Koene 1989] and/or tolerance [Goulmy et al. 1985, Muluk et al. 1991], yet it is also true that drug non-compliance is a common cause of late acute rejection and graft loss in stable kidney recipients [Rao et al. 1988, Didlake et al. 1988, Rao et al. 1989, Hricik et al. 1991]. The latter fact is a warning that immunosuppression should be cautiously and gradually reduced. Patients who reject grafts early tend to require more immunosuppression. It is not known, however, whether patients who do not reject early require less immunosuppression. Herein, we present a case of late acute cellular and vascular rejection that occurred 9 years after stable renal graft function, in the absence of early acute rejection episodes. This case provides evidence to support the notion that lack of early acute rejection may not predict safe reduction of immunosuppression therapy.

Acute Disease↗